Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Aldeyra Therapeutics, Inc.

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Aldeyra Therapeutics, Inc. News provided by Ademi LLP Mar 18, 2026, 12:30 ET Share this article Share to X Share this article Share to X MILWAUKEE , March 18, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Aldeyra (Nasdaq: ALD ). The investigation results from inaccurate statements Aldeyra may have made regarding its financial statements, business operations and prospects. Click here to join our investigation or to obtain additional information, or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. The investigation focuses on whether Aldeyra disclosed problems in its clinical trials for reproxalap for dry eye disease. We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Contact: Ademi LLP Guri Ademi 3620 East Layton Ave. Cudahy, WI 53110 Toll Free: (866) 264-3995 Fax: (414) 482-8001 www.ademilaw.com SOURCE Ademi LLP 21 % more press release views with Request a Demo × Modal title